基于PROISCD-GM(V1.0)慢性胃炎患者最小临床重要性差值的制定

Establishing minimum clinically important difference in patients with chronic gastritis based on the PROISCD-GM(V1.0)

目的制定慢性胃炎PROISCD-GM(V1.0)的最小临床重要性差值(MCID)。方法采用PROISCD-GM(V1.0)及生命质量测定量表(SF-36)在治疗前后对患者进行2次横断面调查,然后采用锚法和分布法计算检验量表各领域及总量表的MCID,结合两种方法加权得到最终的MCID。结果慢性胃炎PROISCD-GM(V1.0)治疗前后得分差异有统计学意义(P<0.001),量表的身体健康、心理健康、社会健康、精神/信仰健康维度和总量表的MCID分别为9.52、9.01、6.25、8.33、8.21分。结论当量表得分超过MCID时,可认为干预措施具有实际临床意义,制定的MCID可为慢性胃炎的相关临床决策和疗效评价提供依据。

Objective To establish the Minimum Clinically Important Difference(MCID)for PROISCD-GM(V1.O)in patients with chronic gastritis.Methods Two cross-sectional surveys were conducted using PROISCD-GM(V1.O)and SF-36 before and after treatment.The MCID for each domain and the total score of the questionnaire were calculated using the anchor and distribution methods.The final MCID was obtained by combining the results from both methods.Results The difference in scores before and after treatment with PROISCD-GM(V1.O)for chronic gastritis was statistically significant(P<0.001).The MCID for the dimensions of physical health,mental health,social health,spiritual/religious health,and the total score were 9.52,9.01,6.25,8.33,and 8.21 points,respectively.Conclusion When the score exceeds the MCID,it can be considered that the intervention measures have practical clinical signifi-cance.The established MCID can provide a basis for relevant clinical decisions and efficacy evaluation in the management of chronic gastritis.